167 related articles for article (PubMed ID: 29522761)
1. Overexpression of prostaglandin E2 EP4 receptor improves cardiac function after myocardial infarction.
Bryson TD; Gu X; Khalil RM; Khan S; Zhu L; Xu J; Peterson E; Yang XP; Harding P
J Mol Cell Cardiol; 2018 May; 118():1-12. PubMed ID: 29522761
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor.
Gu X; Xu J; Zhu L; Bryson T; Yang XP; Peterson E; Harding P
Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27502370
[TBL] [Abstract][Full Text] [Related]
3. Deleterious effects of cardiomyocyte-specific prostaglandin E2 EP3 receptor overexpression on cardiac function after myocardial infarction.
Maxwell DL; Bryson TD; Taube D; Xu J; Peterson E; Harding P
Life Sci; 2023 Jan; 313():121277. PubMed ID: 36521546
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E
Bryson TD; Ross J; Peterson E; Harding P
Prostaglandins Other Lipid Mediat; 2019 Oct; 144():106349. PubMed ID: 31229524
[TBL] [Abstract][Full Text] [Related]
5. Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction.
Qian JY; Harding P; Liu Y; Shesely E; Yang XP; LaPointe MC
Hypertension; 2008 Feb; 51(2):560-6. PubMed ID: 18180401
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury.
Hishikari K; Suzuki J; Ogawa M; Isobe K; Takahashi T; Onishi M; Takayama K; Isobe M
Cardiovasc Res; 2009 Jan; 81(1):123-32. PubMed ID: 18805784
[TBL] [Abstract][Full Text] [Related]
7. Activation of EP4 receptor limits transition of acute to chronic heart failure in lipoxygenase deficient mice.
Kain V; Ingle KA; Rajasekaran NS; Halade GV
Theranostics; 2021; 11(6):2742-2754. PubMed ID: 33456570
[No Abstract] [Full Text] [Related]
8. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4.
Xiao CY; Yuhki K; Hara A; Fujino T; Kuriyama S; Yamada T; Takayama K; Takahata O; Karibe H; Taniguchi T; Narumiya S; Ushikubi F
Circulation; 2004 May; 109(20):2462-8. PubMed ID: 15123528
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological modulation of prostaglandin E
Bosma KJ; Ghosh M; Andrei SR; Zhong L; Dunn JC; Ricciardi VF; Burkett JB; Hatzopoulos AK; Damron DS; Gannon M
Physiol Rep; 2022 Apr; 10(7):e15212. PubMed ID: 35403369
[TBL] [Abstract][Full Text] [Related]
10. The deleterious role of the prostaglandin E
Bryson TD; Pandrangi TS; Khan SZ; Xu J; Pavlov TS; Ortiz PA; Peterson E; Harding P
Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H867-H882. PubMed ID: 32142358
[TBL] [Abstract][Full Text] [Related]
11. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction.
van Rooij E; Doevendans PA; Crijns HJ; Heeneman S; Lips DJ; van Bilsen M; Williams RS; Olson EN; Bassel-Duby R; Rothermel BA; De Windt LJ
Circ Res; 2004 Feb; 94(3):e18-26. PubMed ID: 14739160
[TBL] [Abstract][Full Text] [Related]
12. The prostaglandin EP4 receptor is a master regulator of the expression of PGE
Kashmiry A; Tate R; Rotondo G; Davidson J; Rotondo D
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Oct; 1863(10):1297-1304. PubMed ID: 30053598
[TBL] [Abstract][Full Text] [Related]
13. Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.
Hosono K; Suzuki T; Tamaki H; Sakagami H; Hayashi I; Narumiya S; Alitalo K; Majima M
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1049-58. PubMed ID: 21311040
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E Receptor Subtype 4 Signaling in the Heart: Role in Ischemia/Reperfusion Injury and Cardiac Hypertrophy.
Pang L; Cai Y; Tang EH; Irwin MG; Ma H; Xia Z
J Diabetes Res; 2016; 2016():1324347. PubMed ID: 27190998
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide.
Bonfill-Teixidor E; Otxoa-de-Amezaga A; Font-Nieves M; Sans-Fons MG; Planas AM
J Neuroinflammation; 2017 Jan; 14(1):3. PubMed ID: 28086956
[TBL] [Abstract][Full Text] [Related]
16. Myeloid Cell Prostaglandin E2 Receptor EP4 Modulates Cytokine Production but Not Atherogenesis in a Mouse Model of Type 1 Diabetes.
Vallerie SN; Kramer F; Barnhart S; Kanter JE; Breyer RM; Andreasson KI; Bornfeldt KE
PLoS One; 2016; 11(6):e0158316. PubMed ID: 27351842
[TBL] [Abstract][Full Text] [Related]
17. Fractalkine neutralization improves cardiac function after myocardial infarction.
Gu X; Xu J; Yang XP; Peterson E; Harding P
Exp Physiol; 2015 Jul; 100(7):805-17. PubMed ID: 25943588
[TBL] [Abstract][Full Text] [Related]
18. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.
Li HL; Zhuo ML; Wang D; Wang AB; Cai H; Sun LH; Yang Q; Huang Y; Wei YS; Liu PP; Liu DP; Liang CC
Circulation; 2007 Apr; 115(14):1885-94. PubMed ID: 17389268
[TBL] [Abstract][Full Text] [Related]
19. Fractalkine depresses cardiomyocyte contractility.
Taube D; Xu J; Yang XP; Undrovinas A; Peterson E; Harding P
PLoS One; 2013; 8(7):e69832. PubMed ID: 23936109
[TBL] [Abstract][Full Text] [Related]
20. Signaling of Prostaglandin E Receptors, EP3 and EP4 Facilitates Wound Healing and Lymphangiogenesis with Enhanced Recruitment of M2 Macrophages in Mice.
Hosono K; Isonaka R; Kawakami T; Narumiya S; Majima M
PLoS One; 2016; 11(10):e0162532. PubMed ID: 27711210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
